• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by NeuroMetrix Inc.

    5/2/25 9:29:09 AM ET
    $NURO
    Medical/Dental Instruments
    Health Care
    Get the next $NURO alert in real time by email
    S-8 POS 1 forms-8pos.htm S-8 POS

     

    As filed with the Securities and Exchange Commission on May 2, 2025

     

    Registration No. 333-118059

    Registration No. 333-135242

    Registration No. 333-151195

    Registration No. 333-159712

    Registration No. 333-159713

    Registration No. 333-167180

    Registration No. 333-173769

    Registration No. 333-183071

    Registration No. 333-186827

    Registration No. 333-189393

    Registration No. 333-190177

    Registration No. 333-197407

    Registration No. 333-205827

    Registration No. 333-211379

    Registration No. 333-218431

    Registration No. 333-226245

    Registration No. 333-236105

    Registration No. 333-256489

    Registration No. 333-265080

    Registration No. 333-273478

    Registration No. 333-279414

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Post-Effective Amendment No. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-118059

    Post-Effective Amendment No. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-135242

    Post-Effective Amendment No. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-151195

    Post-Effective Amendment No. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-159712

    Post-Effective Amendment No. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-159713

    Post-Effective Amendment No. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-167180

    Post-Effective Amendment No. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-173769

    Post-Effective Amendment No. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-183071

    Post-Effective Amendment No. 2 TO FORM S-8 REGISTRATION STATEMENT NO. 333-186827

    Post-Effective Amendment No. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-189393

    Post-Effective Amendment No. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-190177

    Post-Effective Amendment No. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-197407

    Post-Effective Amendment No. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-205827

    Post-Effective Amendment No. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-211379

    Post-Effective Amendment No. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-218431

    Post-Effective Amendment No. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-226245

    Post-Effective Amendment No. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-236105

    Post-Effective Amendment No. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-256489

    Post-Effective Amendment No. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-265080

    Post-Effective Amendment No. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-273478
    Post-Effective Amendment No. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-279414

     

    UNDER
    THE SECURITIES ACT OF 1933

     

    NeuroMetrix, Inc.
    (Exact name of registrant as specified in its charter)

     

    Delaware   04-3308180
    (State or other jurisdiction of incorporation or organization)   (I.R.S. Employer Identification No.)
         
    4B Gill Street, Woburn, Massachusetts   01801
    (Address of Principal Executive Offices)   (Zip Code)

     

    NeuroMetrix, Inc. Amended and Restated 1998 Equity Incentive Plan

    NeuroMetrix, Inc. 2004 Employee Stock Purchase Plan

    NeuroMetrix, Inc. 2009 Non-Qualified Inducement Stock Plan

    Neurometrix, Inc. Twelfth Amended and Restated 2004 Stock Option and Incentive Plan

    NeuroMetrix, Inc. 2022 Equity Incentive Plan

    NeuroMetrix, Inc. Employee Stock Purchase Plan

    (Full title of the plans)
     

    Shai N. Gozani, M.D., Ph.D.

    President and Chief Executive Officer

    NeuroMetrix, Inc.

    4B Gill Street

    Woburn, Massachusetts 01801

    (Name and address of agent for service)
     
    (781) 890-9989
    (Telephone number, including area code, of agent for service)

     

    Copies to:

     

    Megan N. Gates, Esq.
    Covington & Burling LLP
    One International Place, Suite 1020
    Boston, MA 02111
    (617) 603-8805

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

      Large accelerated filer  ☐ Accelerated filer  ☐
      Non-accelerated filer  ☒ Smaller reporting company  ☒
        Emerging growth company  ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    These Post-Effective Amendments (these “Post-Effective Amendments”) filed by NeuroMetrix, Inc., a Delaware corporation (the “Registrant”), terminate all offerings and deregister all shares of the Registrant’s common stock, par value $0.0001 per share (the “Shares”), that remain unsold or otherwise unissued under the following Registration Statements on Form S-8 (each, a “Registration Statement”, and collectively, the “Registration Statements”) filed by the Registrant with the U.S. Securities and Exchange Commission (the “SEC”).

     

    ● Registration Statement on Form S-8 (No. 333-118059) pertaining to the registration of the securities described in such Registration Statement, which was filed with the SEC on August 9, 2004.

     

    ● Registration Statement on Form S-8 (No. 333-135242) pertaining to the registration of the securities described in such Registration Statement, which was filed with the SEC on June 22, 2006.

     

    ● Registration Statement on Form S-8 (No. 333-151195) pertaining to the registration of the securities described in such Registration Statement, which was filed with the SEC on May 27, 2008.

     

    ● Registration Statement on Form S-8 (No. 333-159712) pertaining to the registration of the securities described in such Registration Statement, which was filed with the SEC on June 3, 2009.

     

    ● Registration Statement on Form S-8 (No. 333-159713) pertaining to the registration of the securities described in such Registration Statement, which was filed with the SEC on June 3, 2009.

     

    ● Registration Statement on Form S-8 (No. 333-167180) pertaining to the registration of the securities described in such Registration Statement, which was filed with the SEC on May 28, 2010.

     

    ● Registration Statement on Form S-8 (No. 333-173769) pertaining to the registration of the securities described in such Registration Statement, which was filed with the SEC on April 28, 2011.

     

    ● Registration Statement on Form S-8 (No. 333-183071) pertaining to the registration of the securities described in such Registration Statement, which was filed with the SEC on August 3, 2012.

     

    ● Registration Statement on Form S-8 (No. 333-186827), pertaining to the registration of the securities described in such Registration Statement, which was originally filed with the SEC on February 25, 2013.

     

    ● Registration Statement on Form S-8 (No. 333-189393) pertaining to the registration of the securities described in such Registration Statement, which was filed with the SEC on June 17, 2013.

     

    ● Registration Statement on Form S-8 (No. 333-190177) pertaining to the registration of the securities described in such Registration Statement, which was filed with the SEC on July 26, 2013.

     

    ● Registration Statement on Form S-8 (No. 333-197407) pertaining to the registration of the securities described in such Registration Statement, which was filed with the SEC on July 14, 2014.

     

    ● Registration Statement on Form S-8 (No. 333-205827) pertaining to the registration of the securities described in such Registration Statement, which was filed with the SEC on July 23, 2015.

     

    ● Registration Statement on Form S-8 (No. 333-211379) pertaining to the registration of the securities described in such Registration Statement, which was filed with the SEC on May 13, 2016.

     

     

     

     

    ● Registration Statement on Form S-8 (No. 333-218431) pertaining to the registration of the securities described in such Registration Statement, which was filed with the SEC on June 1, 2017.

     

    ● Registration Statement on Form S-8 (No. 333-226245) pertaining to the registration of the securities described in such Registration Statement, which was filed with the SEC on July 19, 2018.

     

    ● Registration Statement on Form S-8 (No. 333-236105) pertaining to the registration of the securities described in such Registration Statement, which was filed with the SEC on January 28, 2020.

     

    ● Registration Statement on Form S-8 (No. 333-256489) pertaining to the registration of the securities described in such Registration Statement, which was filed with the SEC on May 26, 2021.

     

    ● Registration Statement on Form S-8 (No. 333-265080) pertaining to the registration of the securities described in such Registration Statement, which was filed with the SEC on May 19, 2022.

     

    ● Registration Statement on Form S-8 (No. 333-273478) pertaining to the registration of the securities described in such Registration Statement, which was filed with the SEC on July 27, 2023.

     

    ● Registration Statement on Form S-8 (No. 333-279414) pertaining to the registration of the securities described in such Registration Statement, which was filed with the SEC on May 15, 2024.

     

    Pursuant to an Agreement and Plan of Merger (the “Merger Agreement”), dated as of December 17, 2024, among the Registrant, electroCore, Inc. a Delaware corporation (“Parent”), and Nexus Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), Merger Sub was merged with and into the Registrant (the “Merger”), with the Registrant continuing as the surviving corporation and a wholly owned subsidiary of Parent. The Merger became effective on May 1, 2025.

     

    In connection with the closing of the Merger, the offerings pursuant to the Registration Statements have been terminated. In accordance with undertakings made by the Registrant in the Registration Statements to remove from registration, by means of a post-effective amendment, any of the securities that remain unsold at the termination of the offerings, the Registrant hereby removes from registration all Shares registered under the Registration Statements but not sold under the Registration Statements.

     

    The foregoing description of the Merger, the Merger Agreement and the transactions contemplated thereby does not purport to be complete and is subject to, and qualified in its entirety by, the Merger Agreement, which is attached as Exhibit 2.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on December 17, 2024.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused these Post-Effective Amendments to be signed on its behalf by the undersigned, thereunto duly authorized, in Woburn, Massachusetts on May 2, 2025:

     

      NEUROMETRIX, INC.
         
      By: /s/ Shai N. Gozani, M.D., Ph.D.
      Name: Shai N. Gozani, M.D., Ph.D.
      Title: President and Chief Executive Officer

     

    No other person is required to sign this Post-Effective Amendment in reliance upon Rule 478 under the Securities Act of 1933, as amended.

     

     

     

    Get the next $NURO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NURO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NURO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Horowitz Joshua returned 90,307 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - NeuroMetrix, Inc. (0001289850) (Issuer)

    5/5/25 6:51:59 PM ET
    $NURO
    Medical/Dental Instruments
    Health Care

    Director Goodman David returned 7,602 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - NeuroMetrix, Inc. (0001289850) (Issuer)

    5/5/25 5:53:03 PM ET
    $NURO
    Medical/Dental Instruments
    Health Care

    Director Van Avermaete David returned 7,601 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - NeuroMetrix, Inc. (0001289850) (Issuer)

    5/5/25 5:53:02 PM ET
    $NURO
    Medical/Dental Instruments
    Health Care

    $NURO
    SEC Filings

    View All

    SEC Form 15-12G filed by NeuroMetrix Inc.

    15-12G - NeuroMetrix, Inc. (0001289850) (Filer)

    5/12/25 4:05:30 PM ET
    $NURO
    Medical/Dental Instruments
    Health Care

    SEC Form EFFECT filed by NeuroMetrix Inc.

    EFFECT - NeuroMetrix, Inc. (0001289850) (Filer)

    5/6/25 12:15:11 AM ET
    $NURO
    Medical/Dental Instruments
    Health Care

    SEC Form EFFECT filed by NeuroMetrix Inc.

    EFFECT - NeuroMetrix, Inc. (0001289850) (Filer)

    5/6/25 12:15:15 AM ET
    $NURO
    Medical/Dental Instruments
    Health Care

    $NURO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    electroCore Completes Acquisition of NeuroMetrix, Gaining Access to its Quell Platform, Creating Significant Player in Non-Invasive Bioelectronic Technologies

    ROCKAWAY, N.J., May 02, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. ("ECOR," "electroCore," or the "Company") (NASDAQ:ECOR), a commercial-stage bioelectronic technology company, announced today the completion of the merger (the "Merger") with NeuroMetrix, Inc. ("NeuroMetrix" or "NURO") (NASDAQ:NURO), positioning itself as a diversified leader in non-invasive health and wellness solutions. The acquisition of NeuroMetrix's Quell® Fibromyalgia Solution expands electroCore's portfolio of non-invasive bioelectronic therapies, strengthens its commercial reach — particularly within the VA Hospital System — and is expected to meaningfully increase its addressable market for the treatment of chroni

    5/2/25 8:00:00 AM ET
    $ECOR
    $NURO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Medical/Dental Instruments

    electroCore to Acquire NeuroMetrix, Gaining Access to its Quell Platform and Positioning Itself as a Significant Player in Non-Invasive Bioelectronic Medicine and Wellness

    The Quell® platform will strengthen our position as a significant player in the bioelectronic health and wellness sector Company to discuss acquisition and host investor Q&A in a webcast today at 4:30 p.m. EST ROCKAWAY, N.J., Dec. 17, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. ("ECOR," "electroCore," or the "Company") (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today it has entered into a definitive agreement to acquire NeuroMetrix, Inc. ("NeuroMetrix" or "NURO") (NASDAQ:NURO), including its Quell platform, positioning itself as a diversified, commercial-scale player in non-invasive health and wellness treatments. NURO is a commercial stage h

    12/17/24 4:05:00 PM ET
    $ECOR
    $NURO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Medical/Dental Instruments

    NeuroMetrix to be Acquired by electroCore

    WOBURN, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. ("NeuroMetrix" or the "Company") (NASDAQ:NURO) today announced it has entered into a definitive merger agreement whereby electroCore, Inc. ("electroCore") (NASDAQ:ECOR), a commercial stage bioelectronic medicine and wellness company, will acquire NeuroMetrix. The transaction has been unanimously approved by the Boards of Directors of both companies and is expected to close late in the first quarter of 2025. Under the terms of the merger agreement, a subsidiary of electroCore will merge with NeuroMetrix and NeuroMetrix will become a wholly owned subsidiary of electroCore. The shareholders of NeuroMetrix will be entitled to

    12/17/24 4:05:00 PM ET
    $ECOR
    $NURO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Medical/Dental Instruments

    $NURO
    Leadership Updates

    Live Leadership Updates

    View All

    NeuroMetrix Announces Steps Taken to Enhance Shareholder Value

    Joshua S. Horowitz joins Board of DirectorsAt-the-market equity facility terminated WOBURN, Mass., April 19, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) today announced two steps to enhance shareholder value following feedback and recommendations from one of its largest shareholders, Ephraim Fields of Echo Lake Capital. The Board has approved the appointment of Joshua S. Horowitz as a new independent director with a 1-year term. Mr. Horowitz is a professional investor with over 22 years of investing experience. Since January 2012, he has served as a portfolio manager with Palm Management (US) LLC. Mr. Horowitz also brings extensive public company board experience. Earlie

    4/19/24 8:00:00 AM ET
    $NURO
    Medical/Dental Instruments
    Health Care

    NeuroMetrix Names Jonathan Breck Harmel as National Director of Sales for its Emerging Prescription Neurotherapeutics Business

    WOBURN, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) today announced that it has appointed Jonathan "Breck" Harmel as National Director of Sales, Neuromodulation. Mr. Harmel will be responsible for leading the sales organization for the Company's prescription wearable neurotherapeutics business in the U.S. market. The Company recently received FDA De Novo authorization to market its Quell® device as an aid for reducing the symptoms of fibromyalgia in adults with high pain sensitivity. The Company received FDA Breakthrough Designation for the use of Quell to treat fibromyalgia in July 2021. Mr. Harmel brings 15 years of experience in high growth medical technol

    9/1/22 9:00:00 AM ET
    $NURO
    Medical/Dental Instruments
    Health Care

    NeuroMetrix Appoints Brad Fluegel to its Board of Directors

    WOBURN, Mass., June 28, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) today announced the appointment of Bradley M. Fluegel to its Board of Directors, effective as of July 1, 2022. Mr. Fluegel has a broad commercial and advisory background with concentrated industry experience in healthcare and medical technology. He has held numerous leadership roles over the past 25+ years, primarily in healthcare strategy and business development. Most recently, Mr. Fluegel was Senior Vice President, Chief Healthcare Commercial Market Development Officer for Walgreens Co. In this role he was responsible for leading all commercial healthcare activities, including sales and contracting, biopha

    6/28/22 9:00:00 AM ET
    $NURO
    Medical/Dental Instruments
    Health Care

    $NURO
    Financials

    Live finance-specific insights

    View All

    electroCore to Acquire NeuroMetrix, Gaining Access to its Quell Platform and Positioning Itself as a Significant Player in Non-Invasive Bioelectronic Medicine and Wellness

    The Quell® platform will strengthen our position as a significant player in the bioelectronic health and wellness sector Company to discuss acquisition and host investor Q&A in a webcast today at 4:30 p.m. EST ROCKAWAY, N.J., Dec. 17, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. ("ECOR," "electroCore," or the "Company") (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today it has entered into a definitive agreement to acquire NeuroMetrix, Inc. ("NeuroMetrix" or "NURO") (NASDAQ:NURO), including its Quell platform, positioning itself as a diversified, commercial-scale player in non-invasive health and wellness treatments. NURO is a commercial stage h

    12/17/24 4:05:00 PM ET
    $ECOR
    $NURO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Medical/Dental Instruments

    NeuroMetrix Reports Q2 2024 Business Highlights and Update on Review of Strategic Options

    WOBURN, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) today reported financial and business highlights for the quarter and six months ended June 30, 2024. The Company's mission is to reduce the impact of neurological disorders and pain syndromes through innovative non-invasive medical devices. In February of this year, the Company announced that it had initiated a review of strategic options with an objective of enhancing shareholder value. Over the past six months, the Company has invested considerable effort in evaluating a number of specific strategic directions and also making financial, operational and commercial optimizations. In collaboration with a fina

    8/6/24 7:00:00 AM ET
    $NURO
    Medical/Dental Instruments
    Health Care

    NeuroMetrix, Inc. Announces Date for Second Quarter 2024 Business Highlights Conference Call

    WOBURN, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) announced today that it plans to issue its 2024 second quarter business and financial highlights before the opening of the market on August 6, 2024. The Company will host a conference call at 8:00 a.m., Eastern Time on August 6, 2024. For participants who wish to access the Q2 2024 Conference Call live via telephone and be able to ask questions, please register in advance here. Upon registering, a dial-in and unique PIN will be provided on screen and via email to join the call. An audio-only webcast of the call, along with the earnings press release and accompanying condensed financial statements, may be acce

    7/31/24 2:03:34 PM ET
    $NURO
    Medical/Dental Instruments
    Health Care

    $NURO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by NeuroMetrix Inc.

    SC 13G - NeuroMetrix, Inc. (0001289850) (Subject)

    9/27/24 3:56:52 PM ET
    $NURO
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D/A filed by NeuroMetrix Inc. (Amendment)

    SC 13D/A - NeuroMetrix, Inc. (0001289850) (Subject)

    3/4/24 4:12:13 PM ET
    $NURO
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D filed by NeuroMetrix Inc.

    SC 13D - NeuroMetrix, Inc. (0001289850) (Subject)

    2/27/24 4:00:09 PM ET
    $NURO
    Medical/Dental Instruments
    Health Care